Somewhat Positive Press Coverage Very Likely to Affect Jazz Pharmaceuticals plc – (JAZZ) Share Price

Headlines about Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) have been trending somewhat positive this week, according to Alpha One Sentiment. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jazz Pharmaceuticals plc – earned a news sentiment score of 0.09 on Alpha One’s scale. Alpha One also gave headlines about the specialty pharmaceutical company an impact score of 82 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the immediate future.

A number of equities research analysts recently issued reports on JAZZ shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $187.00 target price on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, January 12th. BMO Capital Markets reissued an “outperform” rating and set a $192.00 price target on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, January 12th. Barclays PLC reissued an “overweight” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, January 18th. Mizuho reissued a “neutral” rating and set a $127.00 price target on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, January 18th. Finally, Goldman Sachs Group Inc reissued a “buy” rating and set a $170.00 price target on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, January 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company. Jazz Pharmaceuticals plc – presently has a consensus rating of “Buy” and an average target price of $181.23.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 1.13% during trading on Friday, hitting $152.48. 160,803 shares of the stock traded hands. The company has a market cap of $9.11 billion, a PE ratio of 23.79 and a beta of 1.22. The firm has a 50 day moving average price of $143.48 and a 200-day moving average price of $123.54. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $160.00.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 EPS for the quarter, missing the consensus estimate of $2.65 by $0.74. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The firm earned $396.62 million during the quarter, compared to the consensus estimate of $398.91 million. During the same period in the prior year, the business earned $2.60 earnings per share. Jazz Pharmaceuticals plc -‘s quarterly revenue was up 16.4% compared to the same quarter last year. Analysts anticipate that Jazz Pharmaceuticals plc – will post $11.10 earnings per share for the current fiscal year.

In other news, SVP Paul Treacy sold 884 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $131.97, for a total value of $116,661.48. Following the sale, the senior vice president now directly owns 18,108 shares in the company, valued at approximately $2,389,712.76. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $152.56, for a total transaction of $30,512.00. Following the completion of the sale, the senior vice president now owns 22,562 shares in the company, valued at $3,442,058.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,942 shares of company stock worth $2,098,147. Insiders own 3.90% of the company’s stock.

WARNING: This piece of content was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/21/somewhat-favorable-press-coverage-very-likely-to-effect-jazz-pharmaceuticals-plc-jazz-share-price-updated.html.

Jazz Pharmaceuticals plc – Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply